HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mastroroberto, P. Articles by Marchese, A. R. Search for Related Content PubMed PubMed Citation Articles by Mastroroberto, P. Articles by Marchese, A. R.

European Journal of Cardio-Thoracic Surgery, Vol 9, 143-145, Copyright © 1995 by European Association for Cardio-thoracic Surgery

ARTICLES

Suppressed fibrinolysis after administration of low-dose aprotinin: reduced level of plasmin-alpha2-plasmin inhibitor complexes and postoperative blood loss

P Mastroroberto, M Chello, S Zofrea and AR Marchese
Cardiovascular Surgery Unit, University Hospital, Catanzaro, Italy.

Various clinical investigation have shown that aprotinin therapy reduces bleeding after open-heart operations. In this study low-dose aprotinin, 30,000 KIU/kg in the cardiopulmonary bypass (CPB) priming volume and 7,500 KIU/kg intravenously each hour during CPB, was used in ten patients undergoing primary myocardial revascularization or surgery for valvular diseases. Another ten patients served as controls. Blood loss, platelet count and plasma levels of hemoglobin, antithrombin III, fibrinogen, fibrinogen degradation products (FDP), total plasmin inhibitor and alpha2-plasmin inhibitor-plasmin complexes were evaluated at nine preoperative, intraoperative and postoperative points. Intraoperative and postoperative blood loss was significantly reduced in the aprotinin group. There was no significant difference between the two groups in platelet count and levels of hemoglobin and antithrombin III. A significant increase in FDP during CPB in the control group indicated hyperfibrinolysis. The levels of plasmin inhibitor were significantly reduced during CPB in the control group. The alpha 2- plasmin inhibitor-plasma complex levels, indicating the plasmin activity, were significantly reduced in the aprotinin group. These results confirmed that low-dose aprotinin reduced blood loss with the prevention of hyperfibrinolysis during CPB and demonstrated improved hemostasis.

This article has been cited by other articles:

				K. Kottke-Marchant and S. Sapatnekar Hemostatic Abnormalities in Cardiopulmonary Bypass: Pathophysiologic and Transfusion Considerations Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 187 - 206. [Abstract] [PDF]

				R. J. Dignan, D. W. Law, P. W. Seah, C. W. Manganas, D. C. Newman, P. W. Grant, and H. D. Wolfenden Ultra-low dose aprotinin decreases transfusion requirements and is cost effective in coronary operations Ann. Thorac. Surg., January 1, 2001; 71(1): 158 - 164. [Abstract] [Full Text] [PDF]

				M. Misfeld, S. Dubbert, S. Eleftheriadis, H.-J. Siemens, T. Wagner, and H.-H. Sievers Fibrinolysis-adjusted perioperative low-dose aprotinin reduces blood loss in bypass operations Ann. Thorac. Surg., September 1, 1998; 66(3): 792 - 799. [Abstract] [Full Text] [PDF]

				E. M. Boyle Jr, E. D. Verrier, and B. D. Spiess Endothelial Cell Injury in Cardiovascular Surgery: The Procoagulant Response Ann. Thorac. Surg., November 1, 1996; 62(5): 1549 - 1557. [Abstract] [Full Text]